| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | RECRUITING | PHASE3 | 2025-02-03 | 2029-04 | 2029-04 |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE2 | 2024-10-14 | 2026-12 | 2026-12 |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | RECRUITING | PHASE3 | 2024-07-31 | 2028-10 | 2028-10 |
| NCT06390059 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-08-28 | 2025-11-27 | 2025-11-27 |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | TERMINATED | PHASE2 | 2021-07-12 | 2025-01-10 | 2025-01-10 |
| NCT04953234 | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge | COMPLETED | NA | 2021-02-23 | 2021-04-26 | 2021-04-26 |
| NCT04471844 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | ACTIVE_NOT_RECRUITING | NA | 2020-12-08 | 2026-01-30 | 2026-01-30 |
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | COMPLETED | PHASE2 | 2020-07-14 | 2023-06-20 | 2023-06-20 |
| NCT04281576 | Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | COMPLETED | NA | 2019-12-19 | 2024-06-07 | 2024-06-07 |
| NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | COMPLETED | PHASE3 | 2019-03-22 | 2023-05-18 | 2023-05-18 |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | COMPLETED | PHASE2 | 2019-02-15 | 2021-01-14 | 2021-01-14 |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | COMPLETED | PHASE3 | 2018-02-10 | 2024-10-16 | 2024-10-16 |
| NCT03780569 | TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM | UNKNOWN | NA | 2017-04-27 | 2019-01 | 2019-01 |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | COMPLETED | PHASE3 | 2016-12 | 2024-10-09 | 2024-09-24 |
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | COMPLETED | PHASE3 | 2016-07 | 2024-11-29 | 2024-11-29 |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | COMPLETED | PHASE2 | 2015-02 | 2018-04 | 2018-04 |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | UNKNOWN | PHASE1, PHASE2 | 2014-09 | 2016-12 | 2016-12 |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | UNKNOWN | PHASE1, PHASE2 | 2013-11 | 2017-12 | 2017-12 |
| NCT01755624 | Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) | UNKNOWN | PHASE2 | 2013-01 | 2017-07 | 2017-07 |
| NCT01756729 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | TERMINATED | PHASE4 | 2012-12 | 2018-01 | 2018-01 |
| NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | COMPLETED | PHASE3 | 2009-06 | 2017-03 | 2016-12 |
| NCT00749346 | NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer | COMPLETED | PHASE1, PHASE2 | 2008-05 | 2011-07 | 2011-07 |
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | COMPLETED | PHASE3 | 2006-09 | 2011-01 | 2009-11 |